Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Прекращено Россия

REALITY Advanced

The Natural History of Coronary Atherosclerosis Within the Concept of the Glagovian Arterial Remodeling in REAL-world Stable Chest Pain Population Who Underwent nonInvasive compuTed tomographY Angiography in Comparison With Invasive Quantitative Coronary Angiography and Multimodality Imaging Handled by the Advanced Post-processing Software: Clinical potentIal and Safety

Номер протоколаREALITY Advanced
ФазаФаза не указана
Участников по плану — во всех странах исследования1 080
Сроки01.05.2015 — 01.08.2022
Начало: 1 мая 2015Окончание: 1 августа 2022
Плановый срок исследования истёк

Постоянная ссылка: https://clinomir.ru/trials/nct/NCT02440646/

Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда

Простыми словами

Словарь терминов
  • Исследование прекращено досрочно, новых участников не набирают.
  • Возраст участников: 40–79 лет. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 1080 чел. во всех странах исследования.
  • Центров в реестре: 1 в одном городе. Список — ниже на странице.
  • Плановая дата окончания (08.2022) уже прошла.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возраст40–79 лет
ПолЛюбой
Здоровые добровольцынет

Главное из критериев

  • ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения

Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.

Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 6 · невключение: 38

Критерии включения

  • all stable chest pain comers with chronic coronary syndrome or angina equivalent consistent with the manifestation of the stable coronary artery disease (by the 2019 Guidelines on Chronic Coronary Syndrome);
  • age between 40 and 79 years old;
  • patient must have one or two-vessel disease in a native coronary vessel requiring or not requiring PCI without indications for immediate bypass surgery with any SYNTAX score;
  • lesions may be either de novo or restenotic;
  • successful, uncomplicated PCI could be performed in the culprit vessels and all culprit lesions, but there should be no events or complications between the procedures of PCI in the past and six months before admission to the Chest Pain Center;
  • the non-culprit vessel should have no flow-limiting lesions (but any plaque burden) and be available for imaging. The non-culprit vessel must be considered safe for imaging evaluation;

Критерии невключения

  • any acute comorbidities;
  • patient has had a documented ST-elevation acute myocardial infarction within the 24 hours or acute coronary syndrome (unstable angina, myocardial infarction) during four weeks before admission to the Chest Pain Center;
  • patient has had a recent PCI (last 6 months before admission to the Chest Pain Center) unless the patient is undergoing a staged procedure for dual vessel treatment;
  • unprotected left main lesion location;
  • imaging evidence of severe calcification (CCTA calcium scoring with a CAC>1000) or marked tortuosity of the vessel;
  • culprit lesion is located within or distal to an arterial or saphenous vein graft;
  • untreated, significant coronary lesion with a >50-75% diameter stenosis remaining in the culprit vessel after the planned intervention (branch stenosis is permitted) unless allowed by the Heart Team, or the Institutional Review Board (IRB), or the Data Safety and Monitoring Board (DSMB);
  • lesion or vessel contains visible thrombus within the imaging procedure;
  • patient has an additional lesion that requires intervention within 180 days after the initial hospitalization unless allowed by the Heart Team, or the IRB, or the DSMB;
  • any diameter stenosis more than 75% in the non-culprit vessel;
  • indications for immediate bypass surgery within one year of enrollment with the SYNTAX above 34 (including multi-vessel disease requiring intervention in all three major coronary arteries);
  • decompensated hypotension or heart failure requiring intubation, inotropes, intravenous diuretics, or intra-aortic balloon counterpulsation (including the presence of cardiogenic shock);
  • patient has a known left ventricular ejection fraction <40% or history of decompensated congestive heart failure;
  • uncontrolled tachycardia or refractory ventricular arrhythmia;
  • presence of cardiac implants;
  • acute conduction system disease requiring a pacemaker;
  • uncontrolled hypokalemia or digitalis intoxication;
  • uncontrolled arterial hypertension;
  • moderate or severe pulmonary hypertension with pulmonary artery systolic pressure >35 mmHg;
  • severe disorders of blood coagulation system/ coagulopathy;
  • fever; active infective endocarditis; active COVID-19 infection; any active or severe chronic viral infections; sepsis;
  • HIV infection: CDC acute retroviral syndrome/ acute HIV infection, CDC stage 3/ WHO stage 4 (AIDS; the CD4+ cell count is less than 200 or the percent of CD4+ cells is less than 15% of all lymphocytes); however, the subjects of the HIVE trial (NCT04810364) are allowed, but with chronic HIV infection (CDC stages 1, 2/ WHO stages 1, 2, 3) only;
  • tuberculosis;
  • creatinine clearance with GFR of <45 mL/min/1.73 m2 (severe CKD, G3b-G4-G5) by CKD-EPI (2009) or <45 mL/min by Cockroft-Gault (1976); a few reasons are there for these limitations, a) many medications are contraindicated and/ or dosages must be decreased in patients with severe CKD, b) already-in-use metformin with eGFR ≥45 mL/min/1.73 m2 is not an exclusion criterion, and metformin must be not stopped at the time of or before studies with IV contrast or withheld for 48 hours after the procedure, c) to reduce contrast material and radiation dose and therefore to prevent contrast-associated acute kidney injury, all the procedures with intravascular contrast (CCTA, CMR, SPECT, coronary angiography and any related invasive intravascular procedures) cannot be performed altogether subsequently during 24-48 hours, but it must undergo within two weeks with the recommended minimum break time between procedures of 48 hours and proper preventive hydration of the recruited patients.
  • need for dialysis;
  • liver cirrhosis;
  • severe endocrine disorders (diabetes is permitted) including pre-existing thyroid diseases unless allowed by the Heart Team, or the IRB, or the DSMB;
  • patient has a known hypersensitivity, allergy, or contraindication to any of the following: aspirin, heparin, clopidogrel, and ticlopidine, or to contrast (including iodine and gadolinium) that cannot be adequately pre-medicated;
  • severe asthma or chronic obstructive pulmonary disease with FEV-1 below 50%;
  • patient has other severe medical illness or recent history of substance abuse that may cause non-compliance; confound the data interpretation or is associated with an anticipated limited life expectancy of less than one year;
  • stage IV cancer;
  • patient on the transplant waiting list;
  • moderate and severe anemia with hemoglobin below 11.0 g/dL, any severe blood diseases;
  • acute or recent history of gastrointestinal bleeding;
  • pregnancy;
  • stroke or CVA within three months before admission to the Chest Pain Center;
  • mental diseases, claustrophobia, inability for patient cooperation;
  • prior participation in this study or patient is currently enrolled in another investigational use device, imaging, or drug study that has not been reached its primary endpoint.

Источник: ClinicalTrials.gov, NCT02440646 · запись обновлена в реестре 30 августа 2022.

Дизайн и результаты

ДизайнНаблюдательное
Включено участников (факт, все страны)1 080
Результатыв реестре не опубликованы
Почему остановлено (как в реестре): The study is terminated due to cessation of the research collaboration with Russian institutions
Что измеряют — первичные конечные точки (8), вторичных — 16
  • Change of per cent of plaque burden from baseline to follow-up as assessed by either CCTA or QCA — At 12 months after the baseline imaging procedure
  • Number of participants with major adverse cardiac events that are related to plaque burden — At 12 months after the baseline imaging procedure
  • Head-to-head comparison between non-invasive (CCTA, FFR-CT, CMR, SPECT, Echo) and invasive imaging (QCA, FFR, QFR, OCT, IVUS, VH-IVUS) — At baseline and 12 months after the baseline imaging procedure
  • Non-invasive imaging for risk stratification — At 12 months after the baseline imaging procedure
  • Invasive imaging for risk stratification — At 12 months after the baseline imaging procedure
  • Diagnostic accuracy of non-invasive and invasive imaging — At baseline and 12 months after the baseline imaging procedure
  • Progression of atherosclerosis and plaque composition in comparison between non-invasive and invasive imaging methods — At baseline and 12 months after the baseline imaging procedure
  • Comparison between anatomical and functional imaging modalities — At baseline and 12 months after the baseline imaging procedure

Цель исследования

In a prospective international multicenter observational study, 1080 stable chest pain patients (REALITY Advanced registry of CCTA patients) with the suspected chronic coronary syndrome will be enrolled. All of them will undergo computed tomography angiography, CMR and/ or SPECT, and Echo. One of the cohorts will be examined with multimodality invasive imaging including quantitative coronary angiography, FFR, QFR with or without further percutaneous coronary intervention, OCT, and some of them - with IVUS, VH-IVUS. The plaque size and relevant stenosis, a composition of the atherosclerotic lesion, major adverse cardiovascular events (all-cause death, death from cardiac causes, myocardial infarction, or rehospitalization due to unstable or progressive angina, ischemia-driven revascularization) will be judged to be related to either originally treated (culprit) lesions or untreated (non-culprit) lesions. Moreover, the clinical potential of both non-invasive and invasive imaging, as well as anatomical vs functional modalities in two real-world patient flows, will be estimated with the special focus on the natural progression of atherosclerosis, clinical outcomes, and safety (contrast-induced nephropathy, radiocontrast-induced thyroid dysfunction, and radiation dose). The diagnostic accuracy will be analyzed.

The follow-up period will achieve 12 months prospectively with collected clinical events and imaging outcomes which will be determined at the baseline and 12-month follow-up.

The independent ethics expertise will be provided by the Ural State Medical University (Yekaterinburg, Russia) and Central Clinical Hospital of the Russian Academy of Sciences (Moscow, Russia). The monitoring of the clinical data with imaging as well as further CoreLab expertise (expert-level post-processing multimodal imaging software of Medis Imaging B.V., Leiden, The Netherlands) will be provided by De Haar Research Task Force, Amsterdam-Rotterdam, the Netherlands. FFR-CT is scheduled to be assessed by the ElucidVivo Research Edition software from Elucid Bio, Boston, MA, U.S.A.

The REALITY project is a part of the JHWH (Jahweh) International Advanced Cardiovascular Imaging Consortium. The main objective of the Consortium that is uniting international efforts of both Academia and Industry is a synergistic development of the advanced machine-learning imaging software in order to integrate benefits of both non-invasive and invasive imaging providing the daily clinical practice with the robust tool for the anatomical and functional examination of coronary atherosclerosis, PCI-related arterial remodeling, and relevant myocardial function.

Где проходит

1 центр в 1 городе

Откуда эта информация

  • ClinicalTrials.gov (U.S. National Library of Medicine) · NCT02440646 Официальный реестр (США) · загружено 9 ноября 2026
    Номер протокола, название, цель, статус, сроки, число участников, спонсор, центры

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.